<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00761748</url>
  </required_header>
  <id_info>
    <org_study_id>DK189OS</org_study_id>
    <nct_id>NCT00761748</nct_id>
  </id_info>
  <brief_title>Comparison of Two Urostomy Bags (2-piece).</brief_title>
  <official_title>A Comparative, Randomised, Crossover Study With SenSura Uro 2-piece Versus ConvaTec 2-piece Among 30 Urostomy-operated Persons in Germany</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Coloplast A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Coloplast A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Coloplast A/S has developed a new, improved 2-piece product for people with urostomies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The 2-piece product is a part of a new product family, under the brand name SenSura. The aim
      of this investigation is to see how the urology product is perceived and how it performs
      against another 2-piece product from ConvaTec. The device 'ConvaTec 2-piece combihesive
      Natura' is selected as the comparative product because of its similarity to SenSura 2-piece
      product.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Preference of the Two Urostomy Products</measure>
    <time_frame>6 weeks</time_frame>
    <description>Number of participants preferring the SenSura Uro 2 piece product or the reference Convatec 2 piece product.
The subjects are asked via the case report form (questionnaire) at the end of the second cross over period, which of the two products they preferred.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Urostomy Patent</condition>
  <arm_group>
    <arm_group_label>SenSura</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SenSura Uro 2-piece. Is a urostomy bag with the intended use of collecting urine from a stoma. Consist of a base plate and a bag that is attached to the base plate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Convatec</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Convatec Uro 2-piece Is a urostomy bag with the intended use of collecting urine from a stoma. Consist of a base plate and a bag that is attached to the base plate.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Convatec Uro 2-piece</intervention_name>
    <description>Specific name of the device: 'Combihesive Natura® with a Durahesive Convex-It® base plate, 45 mm coupling, moldable (13-22 and 22-33 mm) hole size with boarder tape'.
The subjects are asked to test each of the two products for 21 days plus/minus 3 days in a randomised order and in accordance with their normal frequency of change and normal use pattern. The duration of the clinical investigation should be enough time to identify any difference in user-preference. If the subject is in the middle of testing an urostomy base plate when the test period is turning into the next period, the urostomy base plate can be worn until it needs to be changed. It is not possible to blind the investigation as the appearance of the test- and refer-ence products are very different in the look.</description>
    <arm_group_label>Convatec</arm_group_label>
    <other_name>ConvaTec 2-piece</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SenSura Uro 2-piece</intervention_name>
    <description>SenSura URO 2-piece Extended Wear, convex light, 50 mm coupling, cuttable (15-33 mm)</description>
    <arm_group_label>SenSura</arm_group_label>
    <other_name>SenSura</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be at least 18 years old,

          -  Be able to complete a written consent form

          -  Be able to fill in the Case Report Form

          -  Have a urostomy with a diameter of 33 mm. or less.

          -  Have had the urostomy for 3 months or more.

          -  Use a 2-piece convex (or convex light) normally.

          -  Be able to use SenSura URO 2-piece product

          -  Be able to use ConvaTec, 2-piece product

          -  Be able to handle the product themselves (application, removal and emptying),

        Exclusion Criteria:

          -  In order to be enrolled in the clinical investigation, the subjects must not:

               -  Need to use an ostomy belt

               -  Be currently suffering from any dermatological problems, needing special
                  treatment, on the peristomal skin

               -  Being treated with chemo- or radiation therapy,

               -  Be hospitalized during study enrollment, or have a hospitalization or significant
                  surgery planned during the 4-week study period, or

               -  Be pregnant or breast-feeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Carter, M.Sc</last_name>
    <role>Study Chair</role>
    <affiliation>Coloplast A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Visé Mitteldeutschland GmbH</name>
      <address>
        <city>Magdeburg</city>
        <zip>39114</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 26, 2008</study_first_submitted>
  <study_first_submitted_qc>September 26, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2008</study_first_posted>
  <results_first_submitted>March 8, 2010</results_first_submitted>
  <results_first_submitted_qc>November 29, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 1, 2013</results_first_posted>
  <last_update_submitted>November 29, 2012</last_update_submitted>
  <last_update_submitted_qc>November 29, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 1, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Urostomy,</keyword>
  <keyword>2-piece,</keyword>
  <keyword>preference,</keyword>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The subjects were recruited by the investigators at multiple sites in Germany.</recruitment_details>
      <pre_assignment_details>39 subjects were enrolled in the study, however 9 subjects were excluded from participating in the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sensura Uro 2 Piece First, Then Convatec 2 Piece</title>
          <description>Sensura is a newly developed two piece product for people with urostomies.</description>
        </group>
        <group group_id="P2">
          <title>ConvaTec 2 Piece,First, Then Sensura Uro 2 Piece</title>
          <description>Convatec is the reference product and was chosen because of its similarity with the Sensura appliance.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention (21 +/- 3 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Intervention (21 +/- 3 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Overall Study Population</title>
          <description>Urostomy operated subjects</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68" lower_limit="42" upper_limit="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Preference of the Two Urostomy Products</title>
        <description>Number of participants preferring the SenSura Uro 2 piece product or the reference Convatec 2 piece product.
The subjects are asked via the case report form (questionnaire) at the end of the second cross over period, which of the two products they preferred.</description>
        <time_frame>6 weeks</time_frame>
        <population>The Per protocol (PP) population is analysed. PP-criteria: Subjects fulfill the inclusion and exclusion criteria, do not seriously violate the protocol, are exposed to both products and are evaluable with respect to the primary endpoint (state preference). *One drop out was evaluable, as the subject tried both products and stated a preference.</population>
        <group_list>
          <group group_id="O1">
            <title>Sensura Uro 2 Piece</title>
            <description>The new SenSura Uro 2-piece. Is a urostomy bag with the intended use of collecting urine from a stoma. Consist of a base plate and a bag that is attached to the base plate.</description>
          </group>
          <group group_id="O2">
            <title>Convatec 2 Piece</title>
            <description>The reference product Convatec 2 piece is a urostomy bag intended for collecting urin from a stoma.</description>
          </group>
        </group_list>
        <measure>
          <title>Preference of the Two Urostomy Products</title>
          <description>Number of participants preferring the SenSura Uro 2 piece product or the reference Convatec 2 piece product.
The subjects are asked via the case report form (questionnaire) at the end of the second cross over period, which of the two products they preferred.</description>
          <population>The Per protocol (PP) population is analysed. PP-criteria: Subjects fulfill the inclusion and exclusion criteria, do not seriously violate the protocol, are exposed to both products and are evaluable with respect to the primary endpoint (state preference). *One drop out was evaluable, as the subject tried both products and stated a preference.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Sensura Uro 2 Piece</title>
          <description>SenSura Uro 2-piece. Is a urostomy bag with the intended use of collecting urine from a stoma. Consist of a base plate and a bag that is attached to the base plate.</description>
        </group>
        <group group_id="E2">
          <title>Convatec 2 Piece</title>
          <description>The reference product Convatec 2 piece is a urostomy bag intended for collecting urine from a stoma.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin irritation</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of Medical Outcome</name_or_title>
      <organization>Coloplast A/S</organization>
      <email>dkbir@coloplast.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

